Citizens JMP raised the firm’s price target on Taysha Gene Therapies (TSHA) to $8 from $6 and keeps an Outperform rating on the shares. Taysha Gene Therapies reported Q3 results and provided a safety update on 12 dosed patients and a finalized statistical analysis plan that is achievable based on available data, the analyst tells investors in a research note. Finalized REVEAL plans have weathered the regulatory storm, and Citizens believes the protocol is currently the best approach in Rett, giving Taysha a significant competitive advantage.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies Advances TSHA-102 Program
- Taysha Gene Therapies’ Earnings Call Highlights Progress and Challenges
- Taysha Gene Therapies: Advancing REVEAL Study and Mitigating Regulatory Risks Earns Buy Rating
- Taysha Gene Therapies files automatic mixed securities shelf
- Taysha Gene Therapies Amends Sales Agreement, Expands Offering